IRCT20190122042450N1尚未招募2 期
Comparison of the effect of Empagliflozin with Placebo on liver steatosis change in fibroscan in non diabetic patients with nonalcoholic fatty liver disease
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 years 至 65 years（—）
- 性别
- All
入选标准
- •Body mass index less than 40
- •Alcohol daily consumption <20 g in women and < 30 g in men, for at least 3 consecutive months over 5 years ago
- •Hemoglobin A1c less than 6.5 percent
- •Alanin aminotransferase more than 45 in men and more than 30 in women
- •Creatinin less than 1.5 in men and less than 1.4 in women and glomerular filtration rate more than 45
- •Controlled atenuated parameter more than 230 in fibroscan or fatty liver grade equal and more than 2 in liver sonography
- •Signature of consent form
排除标准
- •Pregnancy, breast feeding
- •Heart failure (class II to IV)
- •History of cardiovascular disease in 3 months ago
- •History of cancer in 2 years ago
- •History of cirrhosis
- •Abnormal TSH (uncontrolled yper or hypothyroidism)
- •Autoimmune hepatitis (abnormal ANA and ASMA)
- •Hepatitis C (positive HCV Ab)
- •Hepatitis B (positive HBS Ag)
- •Consumption of NSAIDs, Amiodarone, Tamoxifen, Fibrate, statin, Zinc, Selenium and vitamin C or other antioxidant drugs, Empagliflozin, Metformin, Pioglitazone, Vitamin E and other fatty liver drugs.
研究者
相似试验
招募中
3 期
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90
尚未招募
3 期
Comparison of therapeutic effect of Empagliflozin (Gloripa) and Sitagliptin (Ziptin) on type 2 Diabetic patientsIRCT20200810048355N1Vice Chancellor for Research, Islamic Aazad University, Najafabad branch128
已完成
2 期
The effect of empagliflozin on nonalcoholic fatty liver disease in diabetic patientsIRCT20190122042450N3Iran University of Medical Sciences105
招募中
2 期
The cardiac effect of pioglitazone and empagliflozin among diabetic patients with NAFLDCondition 1: Nonalcoholic fatty liver disease. Condition 2: Type 2 Diabetes. Condition 3: Cardiomyopathy.Nonalcoholic steatohepatitis (NASH)Type 2 diabetesK75.81CardiomyopathyIRCT20190122042450N5Iran University of Medical Sciences70
已完成
3 期
Comparing the effect of Empagliflozin with Pioglitazone on nonalcoholic fatty liverIRCT20220928056051N1Oroumia University of Medical Sciences60